









Markets
/
Stocks
/
nasdaq-stok
/

Stoke Therapeutics Inc

STOK

23.368USD

+0.628+2.76%

Market hours （ET）Quotes delayed by 15 min

1.28BMarket Cap

24.37P/E TTM



Stoke Therapeutics Inc

23.368

+0.628+2.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

5 / 507

Overall Ranking

61 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

24.222

Target Price

+4.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 194.68% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.55M.

Overvalued

The company’s latest PE is 25.10, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.05M shares, decreasing 8.13% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.94M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 13.82M, representing a year-over-year increase of 186.01%, while its net profit experienced a year-over-year increase of 8.61%.

Score

Industry at a Glance

Previous score

8.33

Change



Financials

9.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.69

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 3.99, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 25.10, which is -108.66% below the recent high of -2.17 and 120.60% above the recent low of -5.17.

Score

Industry at a Glance

Previous score

3.13

Change

0.86

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.55, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Stoke Therapeutics Inc is 24.00, with a high of 35.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.55

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

24.222

Target Price

+4.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Stoke Therapeutics Inc

STOK

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 9.18, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 25.56 and the support level at 18.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.28

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.046

Buy

RSI(14)

73.551

Buy

STOCH(KDJ)(9,3,3)

71.262

Sell

ATR(14)

1.232

High Vlolatility

CCI(14)

69.691

Neutral

Williams %R

32.069

Buy

TRIX(12,20)

1.663

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

23.328

Buy

MA10

22.367

Buy

MA20

20.933

Buy

MA50

16.563

Buy

MA100

13.505

Buy

MA200

11.553

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 115.48%, representing a quarter-over-quarter decrease of 5.85%. The largest institutional shareholder is The Vanguard, holding a total of 2.94M shares, representing 5.36% of shares outstanding, with 6.39% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

2.47M

+1394.59%

Lynx1 Capital Advisors LLC

5.29M

+2.02%

RTW Investments L.P.

5.12M

Baker Bros. Advisors LP

4.63M

Redmile Group, LLC

4.49M

-2.34%

Morgan Stanley & Co. LLC

3.22M

+8.62%

TD Securities, Inc.

3.17M

BlackRock Institutional Trust Company, N.A.

2.83M

+0.04%

The Vanguard Group, Inc.

Star Investors

2.78M

+1.95%

Marshall Wace LLP

2.13M

+124.06%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.18, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.